CYP2D6 polymorphism in patients with eating disorders

E. M. Peñas-Lledó, P. Dorado, Z. Agüera, M. Gratacós, Xavier P. Estivill, F. Fernández-Aranda, A. Llerena

Research output: Contribution to journalArticle

19 Citations (Scopus)


CYP2D6 polymorphism is associated with variability in drug response, endogenous metabolism (that is, serotonin), personality, neurocognition and psychopathology. The relationship between CYP2D6 genetic polymorphism and the risk of eating disorders (ED) was analyzed in 267 patients with ED and in 285 controls. A difference in the CYP2D6 active allele distribution was found between these groups. Women carrying more than two active genes (ultrarapid metabolizers) (7.5 vs 4.6%) or two (67 vs 58.9%) active genes were more frequent among patients with ED, whereas those with one (20.6 vs 30.2%) or zero active genes (4.9 vs 6.3%) were more frequent among controls (P<0.05). Although further research is needed, present findings suggest an association between CYP2D6 and ED. CYP2D6 allele distribution in patients with ED seems related to increased enzyme activity.

Original languageEnglish
Pages (from-to)173-175
Number of pages3
JournalPharmacogenomics Journal
Issue number2
Publication statusPublished - 1 Jan 2012



  • CYP2D6
  • eating disorders
  • pharmacogenetics
  • ultrarapid metabolizers

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Peñas-Lledó, E. M., Dorado, P., Agüera, Z., Gratacós, M., Estivill, X. P., Fernández-Aranda, F., & Llerena, A. (2012). CYP2D6 polymorphism in patients with eating disorders. Pharmacogenomics Journal, 12(2), 173-175.